Charles Russell Speechlys advises on the sale of Xstrahl to Risk Capital Partners
Charles Russell Speechlys in Guildford has advised on the sale of Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology, to Risk Capital Partners as part of a management buyout. The firm acted for Martin Robinson, the majority shareholder and previous CEO, from whom the business was acquired.
Xstrahl is a leading designer and manufacturer of superficial orthovoltage X-ray systems used in the treatment of cancers and dermatological disorders, as well as a pioneer in the development of advanced X–ray systems for pre-clinical radiation biology research. For over 15 years, Xstrahl medical systems have reliably supported healthcare professionals and patients in over 500 clinics around the world. The company, headquartered in Britain with facilities in the US, exports its product to over 25 countries, to primarily hospitals and laboratories.
Risk Capital Partners have acquired the majority stake and are supporting the existing management team led by CEO Adrian Treverton.
Martin Robinson said “The sale of any business must be a daunting prospect for any owner and engaging the correct professional team to support the shareholders through the sale process is crucial to ensure a successful outcome.
After 17 years building and managing a complex technology business in the manufacture of medical devices and systems to assist academic researchers to combat cancer, it was reassuring to work with Geoff, Rebecca and Samuel who provided the customer centric values that the Xstrahl Group had adopted at its core, over this lifetime of achievements for the company.
Supporting both the selling shareholders and the remaining management team backed by Risk Capital required pragmatism, common sense, humour and patience, all of which Charles Russell Speechlys provided in abundance.
As the founder and majority selling shareholder I can only unreservedly recommend the quality and high standard of professional services provided at all hours of the day and night by Rebecca and her colleagues”.
Rebecca Burford commented that “It was a pleasure to assist Martin on the sale of this extremely successful business. The deal further adds to our Corporate team’s experience in the TMT and Healthcare sector, key growth areas for the firm”.
The Charles Russell Speechlys team was led by Corporate Senior Associate Rebecca Burford and Corporate Partner Geoffrey Sparks, and included Corporate Associates Samuel Milne and Abbie Tarrant, Corporate Tax Partner Martin Griffiths and Corporate Tax Associate Elliot Michaelson, and members of the firm’s Technology, Media & Telecommunications and Intellectual Property teams. Lock Dutton Corporate Finance acted for Martin and the other sellers as Lead Advisers.
News & Insights
Charles Russell Speechlys advises Kreos Capital VI (UK) Ltd on growth capital investment in retail monitoring solution BeMyEye
Charles Russell Speechlys has advised Kreos Capital VI (UK) Limited on its €3 million growth capital investment in BeMyEye Holdings Limited.
Avoiding a No Deal scenario when selling your Pharmacy
Key areas from a property perspective that can hold up or prevent a pharmacy business sale.